Mary A Boler, LPC, NCC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 11191 Highway 9 N, Mammoth Spring, AR 72554 Phone: 870-895-3977 Fax: 870-895-3978 |
Marcia Beth Haizlip, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1355 Tate Ave, Mammoth Spring, AR 72554 Phone: 870-625-0273 Fax: 870-625-0275 |
Frances M Smith, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1355 Tate Ave, Mammoth Spring, AR 72554 Phone: 870-625-0273 Fax: 870-625-0275 |
Mrs. Charlotte Ann Featherston, LPC Counselor Medicare: Medicare Enrolled Practice Location: 275 Main St, Mammoth Spring, AR 72554 Phone: 870-907-0848 Fax: 417-322-6099 |
News Archive
A novel Electron Paramagnetic Resonance (EPR) oximetry technique will help clinicians directly measure oxygen and schedule treatments at times of high oxygen levels in cancer and stroke patients to improve outcomes, The EPR team at Dartmouth's Geisel School of Medicine has found.
Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified Arena that an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application (NDA) resubmission will be held in the second quarter of 2012. Confirmation and details of the meeting will be published in the Federal Register.
Bacteriophages, known informally as phages, are viruses that can attack and kill specific bacteria. They occur everywhere in the natural world. Precisely because they are matched to just one specific type of bacteria, researchers and medics hope that phages can be engineered to combat certain bacterial infections.
Tyco International Ltd. announced today that the company has completed the acquisition of Visonic Ltd., a global developer and manufacturer of electronic security systems and components, for approximately $100 million in cash. The acquisition was first announced on September 15, 2011.
Cerapedics, Inc., a medical device company focused on developing and commercializing novel osteobiologic products, announced the results of a prospective, randomized, controlled trial of its i-FACTOR biologic bone graft for patients undergoing posterior lumbar interbody fusion spine procedures.
› Verified 9 days ago